ACRS

Aclaris Therapeutics, Inc.

Price Chart

Latest Quote

$5.66

+0.29 (+5.50%)

Current Price

Previous Close	$5.36
Open	$5.37
Day High	$5.70
Day Low	$5.24
Volume	1,028,500

Fetched: 2026-07-17T19:56:01

Stock Information

Shares Outstanding	139.66M
Total Debt	$1.99M
Cash Equivalents	$105.42M
Revenue	$8.37M
Net Income	$-69.66M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$793.29M
EPS (TTM)	$-0.59
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$689.86M
Sales	$8.37M
Income	$-69.66M
Book/sh	$1.03
Cash/sh	$0.75
Employees	69

Financial Ratios

Quick Ratio	4.03
Current Ratio	4.03
Debt/Eq	1.38

Returns & Margins

ROA	-24.72%
ROE	-48.42%
Operating Margin	-1111.82%

Ownership

Insider Ownership	2.29%
Institutional Ownership	79.64%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-6.85
P/S	94.81
P/B	5.52

Analyst Data

Recommendation	strong_buy
Target Price	$10.00

Technical Indicators

SMA20	$5.28
SMA50	$4.84
SMA200	$3.56
RSI	66.35
ATR	0.3241

Shares Float	113.14M
Short Float	9.34%
Short Ratio	5.76
Volatility	0.77
Rel Volume	0.53

Performance History

Week	+1.79%
Month	+30.88%
Quarter	+42.71%
6 Months	+107.30%
YTD	+97.22%
Year	+259.49%
3 Years	-47.31%
5 Years	-67.71%
10 Years	-71.91%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-07-17	$5.68	1,253,700
2026-07-16	$5.36	2,096,300
2026-07-15	$5.60	6,078,000
2026-07-14	$5.43	832,200
2026-07-13	$5.50	1,087,900
2026-07-10	$5.58	1,401,900
2026-07-09	$5.71	2,047,800
2026-07-08	$5.51	1,214,000
2026-07-07	$5.62	1,380,000
2026-07-06	$5.49	1,193,700
2026-07-02	$5.56	1,942,900
2026-07-01	$5.34	2,405,000
2026-06-30	$5.29	3,207,900
2026-06-29	$5.02	1,840,600
2026-06-26	$5.00	8,838,900
2026-06-25	$4.91	1,329,300
2026-06-24	$4.79	1,482,300
2026-06-23	$4.92	1,865,200
2026-06-22	$4.84	1,818,900
2026-06-18	$4.50	4,322,800

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

📰 Latest News

Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength?

Zacks • 2026-07-01T12:23:00Z

3 Penny Stocks Under $5 Backed by Real Revenue Growth

MarketBeat • 2026-06-20T13:20:00Z

Aclaris Therapeutics, Inc. (ACRS): A Top Penny Stock in Investors Portfolio That Stifel is Bullish On

Insider Monkey • 2026-06-07T17:59:05Z

Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052

MarketBeat • 2026-06-04T19:02:23Z

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates

Zacks • 2026-05-07T12:50:06Z

Rigel Pharmaceuticals (RIGL) Lags Q1 Earnings and Revenue Estimates

Zacks • 2026-05-05T22:05:17Z

Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth

Simply Wall St. • 2026-05-04T10:04:29Z

Aclaris Therapeutics Updates ATI-052 Phase 1 Data, Picks ATI-2138 for Phase 2b in Lichen Planus

MarketBeat • 2026-04-28T14:17:49Z

Aclaris Therapeutics Touts ATI-052 Potential for 3-Month Dosing, More Phase 1 Data Incoming

MarketBeat • 2026-04-14T22:04:57Z

Profound Medical (PROF) Surges 13.0%: Is This an Indication of Further Gains?

Zacks • 2026-03-26T13:25:00Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Reconciled Cost Of Revenue	$7,284,000	$15,458,000	$18,081,000	$11,960,000
Cost Of Revenue	$7,284,000	$15,458,000	$18,081,000	$11,960,000
Total Revenue	$7,826,000	$18,720,000	$31,249,000	$29,752,000
Operating Revenue	$7,826,000	$18,720,000	$31,249,000	$29,495,000
Expenses
Total Expenses	$81,901,000	$71,247,000	$147,563,000	$114,906,000
Other Income Expense	$1,515,000	$-87,491,000	$27,466,000	$-1,754,000
Other Non Operating Income Expenses	$3,815,000	$1,914,000	$8,509,000	$2,946,000
Net Non Operating Interest Income Expense	$7,637,000	$7,953,000	-	-
Operating Expense	$74,617,000	$55,789,000	$129,482,000	$102,946,000
Other Operating Expenses	$-3,815,000	$-1,914,000	-	-
General And Administrative Expense	$21,972,000	$22,203,000	$31,098,000	$25,133,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-64,923,000	$-132,065,000	$-88,481,000	$-86,908,000
Net Interest Income	$7,637,000	$7,953,000	-	-
Interest Income	$7,637,000	$7,953,000	-	-
Normalized Income	$-62,623,000	$-42,660,000	$-107,359,695	$-82,208,000
Net Income From Continuing And Discontinued Operation	$-64,923,000	$-132,065,000	$-88,481,000	$-86,908,000
Total Operating Income As Reported	$-76,375,000	$-141,932,000	$-97,357,000	$-89,854,000
Net Income Common Stockholders	$-64,923,000	$-132,065,000	$-88,481,000	$-86,908,000
Net Income	$-64,923,000	$-132,065,000	$-88,481,000	$-86,908,000
Net Income Including Noncontrolling Interests	$-64,923,000	$-132,065,000	$-88,481,000	$-86,908,000
Net Income Continuous Operations	$-64,923,000	$-132,065,000	$-88,481,000	$-86,908,000
Pretax Income	$-64,923,000	$-132,065,000	$-88,848,000	$-86,908,000
Special Income Charges	$-2,300,000	$-89,405,000	$18,957,000	$-4,700,000
Interest Income Non Operating	$7,637,000	$7,953,000	-	-
Operating Income	$-74,075,000	$-52,527,000	$-116,314,000	$-85,154,000
Gross Profit	$542,000	$3,262,000	$13,168,000	$17,792,000
Net Income Discontinuous Operations	-	-	-	$0
Per Share
Diluted EPS	$-0.53	$-1.71	$-1.27	$-1.33
Basic EPS	$-0.53	$-1.71	$-1.27	$-1.33
Other
Tax Effect Of Unusual Items	$0	$0	$78,305	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-71,321,000	$37,685,000	$-134,408,000	$-79,657,000
Total Unusual Items	$-2,300,000	$-89,405,000	$18,957,000	$-4,700,000
Total Unusual Items Excluding Goodwill	$-2,300,000	$-89,405,000	$18,957,000	$-4,700,000
Reconciled Depreciation	$454,000	$807,000	$863,000	$797,000
EBITDA (Bullshit earnings)	$-73,621,000	$-51,720,000	$-115,451,000	$-84,357,000
EBIT	$-74,075,000	$-52,527,000	$-116,314,000	$-85,154,000
Diluted Average Shares	$122,564,741	$77,296,665	$69,808,855	$65,213,944
Basic Average Shares	$122,564,741	$77,296,665	$69,808,855	$65,213,944
Diluted NI Availto Com Stockholders	$-64,923,000	$-132,065,000	$-88,481,000	$-86,908,000
Restructuring And Mergern Acquisition	$2,300,000	$2,500,000	$-26,900,000	$4,700,000
Research And Development	$52,645,000	$33,586,000	$98,384,000	$77,813,000
Selling General And Administration	$21,972,000	$22,203,000	$31,098,000	$25,133,000
Other Gand A	$7,053,000	$8,634,000	$10,797,000	$8,962,000
Salaries And Wages	$14,919,000	$13,569,000	$20,301,000	$16,171,000
Tax Provision	-	$0	$-367,000	$0
Other Special Charges	-	$86,905,000	$6,629,000	-
Write Off	-	$0	$1,314,000	$0
Impairment Of Capital Assets	-	-	$6,629,000	$0

Fetched: 2026-07-16

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$103,082,000	$155,554,000	$157,179,000	$190,648,000
Total Assets	$160,460,000	$220,327,000	$197,405,000	$254,596,000
Total Non Current Assets	$64,144,000	$94,376,000	$68,549,000	$23,046,000
Other Non Current Assets	$2,771,000	$3,066,000	$4,158,000	$2,732,000
Investmentin Financial Assets	$60,612,000	$90,302,000	$62,771,000	$12,242,000
Current Assets	$96,316,000	$125,951,000	$128,856,000	$231,550,000
Other Current Assets	$5,565,000	$12,357,000	$9,452,000	$13,495,000
Cash Cash Equivalents And Short Term Investments	$90,751,000	$113,594,000	$119,106,000	$217,571,000
Cash And Cash Equivalents	$19,960,000	$24,570,000	$39,878,000	$45,277,000
Receivables	-	$318,000	$298,000	$484,000
Accounts Receivable	-	$318,000	$298,000	$484,000
Goodwill And Other Intangible Assets	-	-	$269,000	$6,973,000
Other Intangible Assets	-	-	$269,000	$6,973,000
Prepaid Assets	-	-	-	-
Debt
Total Debt	-	-	$426,000	$684,000
Current Debt And Capital Lease Obligation	-	-	$426,000	$684,000
Liabilities
Total Liabilities Net Minority Interest	$57,378,000	$64,773,000	$40,226,000	$56,975,000
Total Non Current Liabilities Net Minority Interest	$28,733,000	$33,177,000	$9,274,000	$35,037,000
Other Non Current Liabilities	$12,565,000	$13,139,000	$9,274,000	$34,670,000
Non Current Deferred Liabilities	$16,168,000	$20,038,000	$0	$367,000
Current Liabilities	$28,645,000	$31,596,000	$30,952,000	$21,938,000
Other Current Liabilities	$2,753,000	$2,683,000	$2,628,000	$2,202,000
Current Deferred Liabilities	$3,943,000	$7,817,000	$0	-
Payables And Accrued Expenses	$16,651,000	$16,117,000	$24,414,000	$13,757,000
Payables	$13,158,000	$4,690,000	$8,878,000	$10,351,000
Accounts Payable	$13,158,000	$4,690,000	$8,878,000	$10,351,000
Non Current Deferred Taxes Liabilities	-	-	$0	$367,000
Equity
Common Stock Equity	$103,082,000	$155,554,000	$157,179,000	$197,621,000
Total Equity Gross Minority Interest	$103,082,000	$155,554,000	$157,179,000	$197,621,000
Stockholders Equity	$103,082,000	$155,554,000	$157,179,000	$197,621,000
Gains Losses Not Affecting Retained Earnings	$610,000	$97,000	$-106,000	$-897,000
Other Equity Adjustments	$610,000	$97,000	$-106,000	$-897,000
Retained Earnings	$-967,784,000	$-902,861,000	$-770,796,000	$-682,315,000
Other
Ordinary Shares Number	$120,499,433	$107,850,124	$70,894,889	$66,688,647
Share Issued	$120,499,433	$107,850,124	$70,894,889	$66,688,647
Tangible Book Value	$103,082,000	$155,554,000	$157,179,000	$190,648,000
Invested Capital	$103,082,000	$155,554,000	$157,179,000	$197,621,000
Working Capital	$67,671,000	$94,355,000	$97,904,000	$209,612,000
Total Capitalization	$103,082,000	$155,554,000	$157,179,000	$197,621,000
Additional Paid In Capital	$1,070,255,000	$1,058,317,000	$928,080,000	$880,832,000
Capital Stock	$1,000	$1,000	$1,000	$1,000
Common Stock	$1,000	$1,000	$1,000	$1,000
Preferred Stock	$0	$0	$0	$0
Non Current Deferred Revenue	$16,168,000	$20,038,000	$0	-
Current Deferred Revenue	$3,943,000	$3,890,000	$0	-
Pensionand Other Post Retirement Benefit Plans Current	$5,298,000	$4,979,000	$3,910,000	$5,295,000
Current Accrued Expenses	$3,493,000	$11,427,000	$15,536,000	$3,406,000
Investments And Advances	$60,612,000	$90,302,000	$62,771,000	$12,242,000
Available For Sale Securities	$60,612,000	$90,302,000	$62,771,000	$12,242,000
Net PPE	$761,000	$1,008,000	$1,620,000	$1,099,000
Other Short Term Investments	$70,791,000	$89,024,000	$79,228,000	$172,294,000
Accumulated Depreciation	-	$-4,805,000	$-4,162,000	$-4,035,000
Gross PPE	-	$5,813,000	$5,782,000	$5,134,000
Leases	-	$817,000	$817,000	$1,123,000
Other Properties	-	$3,137,000	$3,154,000	$2,010,000
Machinery Furniture Equipment	-	$1,859,000	$1,811,000	$2,001,000
Properties	-	$0	$0	$0
Treasury Shares Number	-	-	$0	-
Capital Lease Obligations	-	-	$426,000	$684,000
Current Capital Lease Obligation	-	-	$426,000	$684,000
Other Investments	-	-	-	-

Fetched: 2026-07-16

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-47,224,000	$-56,006,000	$-79,634,000	$-68,172,000
Operating Activities
Operating Cash Flow	$-47,113,000	$-20,075,000	$-78,325,000	$-67,567,000
Cash Flow From Continuing Operating Activities	$-47,113,000	$-20,075,000	$-78,325,000	$-67,567,000
Operating Gains Losses	-	-	-	-
Investing Activities
Capital Expenditure	$-111,000	$-35,931,000	$-1,309,000	$-605,000
Investing Cash Flow	$48,365,000	$-69,769,000	$46,220,000	$12,628,000
Cash Flow From Continuing Investing Activities	$48,365,000	$-69,769,000	$46,220,000	$12,628,000
Financing Activities
Issuance Of Capital Stock	$0	$74,913,000	$26,714,000	$72,744,000
Financing Cash Flow	$-5,862,000	$74,536,000	$26,706,000	$72,867,000
Cash Flow From Continuing Financing Activities	$-5,862,000	$74,536,000	$26,706,000	$72,867,000
Net Other Financing Charges	$-5,862,000	$-409,000	$-102,000	$-34,000
Net Common Stock Issuance	$0	$74,913,000	$26,714,000	$72,744,000
Common Stock Issuance	$0	$74,913,000	$26,714,000	$72,744,000
Other
End Cash Position	$19,960,000	$24,570,000	$39,878,000	$45,277,000
Beginning Cash Position	$24,570,000	$39,878,000	$45,277,000	$27,349,000
Changes In Cash	$-4,610,000	$-15,308,000	$-5,399,000	$17,928,000
Proceeds From Stock Option Exercised	$0	$32,000	$94,000	$157,000
Net Investment Purchase And Sale	$49,309,000	$-33,838,000	$47,529,000	$13,233,000
Sale Of Investment	$89,041,000	$86,144,000	$183,204,000	$177,986,000
Purchase Of Investment	$-39,732,000	$-119,982,000	$-135,675,000	$-164,753,000
Net Business Purchase And Sale	$-833,000	$0	-	-
Purchase Of Business	$-833,000	$0	-	-
Net Intangibles Purchase And Sale	$0	$-35,810,000	$0	-
Purchase Of Intangibles	$0	$-35,810,000	$0	-
Net PPE Purchase And Sale	$-111,000	$-121,000	$-1,309,000	$-605,000
Purchase Of PPE	$-111,000	$-121,000	$-1,309,000	$-605,000
Change In Working Capital	$2,672,000	$10,922,000	$9,389,000	$-1,195,000
Change In Other Working Capital	$-3,816,000	$23,927,000	-	-
Change In Payables And Accrued Expense	$350,000	$-8,130,000	$10,518,000	$960,000
Change In Accrued Expense	$-8,097,000	$-3,942,000	$11,991,000	$592,000
Change In Payable	$8,447,000	$-4,188,000	$-1,473,000	$368,000
Change In Account Payable	$8,447,000	$-4,188,000	$-1,473,000	$368,000
Change In Prepaid Assets	$6,138,000	$-4,875,000	$-1,315,000	$-2,294,000
Other Non Cash Items	$2,300,000	$89,405,000	$-20,271,000	$4,700,000
Stock Based Compensation	$12,384,000	$10,856,000	$20,542,000	$15,039,000
Depreciation Amortization Depletion	$454,000	$807,000	$863,000	$797,000
Depreciation And Amortization	$454,000	$807,000	$863,000	$797,000
Net Income From Continuing Operations	$-64,923,000	$-132,065,000	$-88,481,000	$-86,908,000
Change In Receivables	-	$-20,000	$186,000	$139,000
Changes In Account Receivables	-	$-20,000	$186,000	$139,000
Deferred Tax	-	$0	$-367,000	$0
Deferred Income Tax	-	$0	$-367,000	$0
Repayment Of Debt	-	-	$0	$0
Net Issuance Payments Of Debt	-	-	$0	$0
Net Long Term Debt Issuance	-	-	$0	$0
Long Term Debt Payments	-	-	$0	$0
Asset Impairment Charge	-	-	$6,629,000	$0
Issuance Of Debt	-	-	-	$0
Long Term Debt Issuance	-	-	-	$0
Sale Of Business	-	-	-	-
Gain Loss On Sale Of Business	-	-	-	-

Fetched: 2026-07-16